Design and rationale of FOCUS (PX-171-011): a randomized, open-label, phase 3 study of carfilzomib versus best supportive care regimen in patients with relapsed and refractory multiple myeloma (R/R MM)
about
Novel agents for multiple myeloma to overcome resistance in phase III clinical trialsFrom epoxomicin to carfilzomib: chemistry, biology, and medical outcomesTrial Watch: Proteasomal inhibitors for anticancer therapyNovel approaches to treatment of double-refractory multiple myeloma.Specificity of Protein Covalent Modification by the Electrophilic Proteasome Inhibitor Carfilzomib in Human CellsMolecular pathways: turning proteasomal protein degradation into a unique treatment approach.Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study.Emerging therapies targeting the ubiquitin proteasome system in cancerNoncanonical SQSTM1/p62-Nrf2 pathway activation mediates proteasome inhibitor resistance in multiple myeloma cells via redox, metabolic and translational reprogramming.Carfilzomib: a novel agent for multiple myeloma.Management of double-refractory multiple myeloma.The emerging role of carfilzomib combination therapy in the management of multiple myeloma.Carfilzomib and pomalidomide: recent advances in the treatment of multiple myeloma.Carfilzomib for the treatment of patients with relapsed and/or refractory multiple myeloma.The European Medicines Agency Review of Carfilzomib for the Treatment of Adult Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy.Carfilzomib-induced cardiotoxicity mitigated by dexrazoxane through inhibition of hypertrophic gene expression and oxidative stress in rats.Apremilast reversed carfilzomib-induced cardiotoxicity through inhibition of oxidative stress, NF-κB and MAPK signaling in rats.Rutin Attenuates Carfilzomib-Induced Cardiotoxicity Through Inhibition of NF-κB, Hypertrophic Gene Expression and Oxidative Stress.Proteasome inhibitors in cancer therapy.
P2860
Q26822754-E54DD748-595C-47DB-9070-7347317C97DDQ26864557-544B112A-83BD-4853-95C3-D5E872CCD2BDQ28082910-34B030BB-9993-41D7-B1BE-2A144E29E4B0Q34347172-A1761EE1-A38C-4B54-A2D7-85CF2EC0A8A6Q36098363-2CF2B71F-67A8-4375-B39C-CD096C35160AQ36436413-8EE66418-E8BA-461D-BDB8-BEF98B61A065Q37397995-5018DAA1-4228-4925-9FEC-2DEEC10B1755Q37410632-844C07E2-362E-43B4-AA2B-AEBA34448A9DQ37684348-123F323A-C48A-493A-8D23-9A90739BCC00Q38120296-8B7945E5-7F06-4538-BE91-CF2B801C78DCQ38131456-25EFC56C-0E13-4F78-B9A0-F90D4103233BQ38187476-4BE71E7D-0878-4E73-8D97-E7C2BC80FBE0Q38231991-14B576D8-4A3B-45DC-8578-875DC676C35CQ38989789-1468A621-ED28-4DA5-B611-B4890B82DBD5Q45924683-DCD8D477-0A5A-4F45-9B24-BEFD3FA3F0AEQ46592609-0A02F50C-F6B1-4A3D-9F28-618E4AD7AD8AQ51360501-F18D3226-A217-4C6C-9FA8-B6C609B7FCF8Q53230021-20B04F69-6FE2-42BE-8DD7-BEF7C5FDC378Q53752929-61EB3F12-5954-4851-AA47-C8D1C5BAC7AC
P2860
Design and rationale of FOCUS (PX-171-011): a randomized, open-label, phase 3 study of carfilzomib versus best supportive care regimen in patients with relapsed and refractory multiple myeloma (R/R MM)
description
2012 nî lūn-bûn
@nan
2012 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
name
Design and rationale of FOCUS ...... tory multiple myeloma (R/R MM)
@ast
Design and rationale of FOCUS ...... tory multiple myeloma (R/R MM)
@en
type
label
Design and rationale of FOCUS ...... tory multiple myeloma (R/R MM)
@ast
Design and rationale of FOCUS ...... tory multiple myeloma (R/R MM)
@en
prefLabel
Design and rationale of FOCUS ...... tory multiple myeloma (R/R MM)
@ast
Design and rationale of FOCUS ...... tory multiple myeloma (R/R MM)
@en
P2093
P2860
P356
P1433
P1476
Design and rationale of FOCUS ...... tory multiple myeloma (R/R MM)
@en
P2093
Barbara Klencke
Richard Bryce
P2860
P2888
P356
10.1186/1471-2407-12-415
P407
P577
2012-09-19T00:00:00Z
P5875
P6179
1036271222